Smoking a pack a day for a year causes 150 mutations in lung cells
Genetic damage caused by smoking measured in different organs of the body
Scientists have measured the catastrophic genetic damage caused by smoking in different organs of the body and identified several different mechanisms by which tobacco smoking causes mutations in DNA. Researchers at the Wellcome Trust Sanger Institute, the Los Alamos National Laboratory and their collaborators* found smokers accumulated an average of 150 extra mutations in every lung cell for each year of smoking one packet of cigarettes a day.
Reported in the Journal Science, the study provides a direct link between the number of cigarettes smoked in a lifetime and the number of mutations in the tumour DNA. The highest mutation rates were seen in the lung cancers but tumours in other parts of the body also contained these smoking-associated mutations, explaining how smoking causes many types of human cancer.
Tobacco smoking claims the lives of at least six million people every year and, if current trends continue, the World Health Organization predicts more than 1 billion tobacco-related deaths in this century. Smoking has been epidemiologically associated with at least 17 types of human cancer, but until now no-one has seen the mechanisms by which smoking causes many of these cancer types.
Cancer is caused by mutations in the DNA of a cell. In the first comprehensive analysis of the DNA of cancers linked to smoking, researchers studied over 5,000 tumours, comparing cancers from smokers with cancers from people who had never smoked. They found particular molecular fingerprints of DNA damage – called mutational signatures – in the smokers’ DNA, and counted how many of these particular mutations were found in the different tumours.
The authors found that, on average, smoking a pack of cigarettes a day led to 150 mutations in each lung cell every year. These mutations represent individual potential start points for a cascade of genetic damage that can eventually lead to cancer. The numbers of mutations within any cancer cell will vary between individuals, but this study shows the additional mutational load caused by tobacco.
“Before now, we had a large body of epidemiological evidence linking smoking with cancer, but now we can actually observe and quantify the molecular changes in the DNA due to cigarette smoking. With this study, we have found that people who smoke a pack a day develop an average of 150 extra mutations in their lungs every year, which explains why smokers have such a higher risk of developing lung cancer.”
Dr Ludmil Alexandrov First author from Los Alamos National Laboratory
Other organs were also affected, with the study showing that a pack a day led to an estimated average 97 mutations in each cell in the larynx, 39 mutations for the pharynx, 23 mutations for mouth, 18 mutations for bladder, and 6 mutations in every cell of the liver each year.
Until now, it has not been fully understood how smoking increases the risk of developing cancer in parts of the body that don’t come into direct contact with smoke. However, the study revealed different mechanisms by which tobacco smoking causes these mutations, depending on the area of the body affected.
“The results are a mixture of the expected and unexpected, and reveal a picture of direct and indirect effects. Mutations caused by direct DNA damage from carcinogens in tobacco were seen mainly in organs that come into direct contact with inhaled smoke. In contrast, other cells of the body suffered only indirect damage, as tobacco smoking seems to affect key mechanisms in these cells that in turn mutate DNA.”
Professor David Phillips An author on the paper and Professor of Environmental Carcinogenesis at King’s College London
The study revealed at least five distinct processes of DNA damage due to cigarette smoking. The most widespread of these is a mutational signature already found in all cancers. In this case, tobacco smoking seems to accelerate the speed of a cellular clock that mutates DNA prematurely.
“The genome of every cancer provides a kind of ‘archaeological record’, written in the DNA code itself, of the exposures that caused the mutations that lead to the cancer. Our research indicates that the way tobacco smoking causes cancer is more complex than we thought. Indeed, we do not fully understand the underlying causes of many types of cancer and there are other known causes, such as obesity, about which we understand little of the underlying mechanism. This study of smoking tells us that looking in the DNA of cancers can provide provocative new clues to how cancers develop and thus, potentially, how they can be prevented.”
Professor Sir Mike Stratton Joint lead author from the Wellcome Trust Sanger Institute
* Other participating centres include
- University of New Mexico Comprehensive Cancer Center, Albuquerque, USA
- Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
- The Francis Crick Institute, London, UK
- University of Leuven, Belgium
- Addenbrooke’s Hospital National Health Service Trust, Cambridge, UK
- National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan
- RIKEN Center for Integrative Medical Sciences, Tokyo, Japan
- Kyoto University Graduate School of Medicine, Kyoto, Japan
- The University of Tokyo, Minato-ku, Tokyo, Japan
- University of Cambridge, Cambridge, UK
- Human Genetics Foundation, Torino, Italy
- Medical Research Council (MRC)–Public Health England (PHE) Centre for Environment and Health, Imperial College London, London, UK
- King’s College London, MRC-PHE Centre for Environment and Health, London, UK
This work was supported by the Wellcome Trust; the Francis Crick Institute( which is core funded by the UK Medical Research Council, Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King’s College London); a J. Robert Oppenheimer Fellowship; , the National Institute for Health Research; PHE; project EXPOSOMICS; grant agreement 308610-FP7 (European Commission); the Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development; and National Cancer Center Research and Development Funds.
Los Alamos National Laboratory, a multidisciplinary research institution engaged in strategic science on behalf of national security, is operated by Los Alamos National Security, LLC, a team composed of Bechtel National, the University of California, BWXT Government Group, and URS, an AECOM company, for the Department of Energy’s National Nuclear Security Administration. Los Alamos enhances national security by ensuring the safety and reliability of the U.S. nuclear stockpile, developing technologies to reduce threats from weapons of mass destruction and solving problems related to energy, environment, infrastructure, health and global security concerns.
King’s College London is one of the top 25 universities in the world (2016/17 QS World University Rankings) and among the oldest in England. King’s has more than 27,600 students (of whom nearly 10,500 are graduate students) from some 150 countries worldwide, and some 6,800 staff.
King’s has an outstanding reputation for world-class teaching and cutting-edge research. In the 2014 Research Excellence Framework (REF) King’s was ranked 6th nationally in the ‘power’ ranking, which takes into account both the quality and quantity of research activity, and 7th for quality according to Times Higher Education rankings. Eighty-four per cent of research at King’s was deemed ‘world-leading’ or ‘internationally excellent’ (3* and 4*). The university is in the top seven UK universities for research earnings and has an overall annual income of more than £684 million.
The Wellcome Trust Sanger Institute is one of the world’s leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.
Wellcome exists to improve health for everyone by helping great ideas to thrive. We’re a global charitable foundation, both politically and financially independent. We support scientists and researchers, take on big problems, fuel imaginations and spark debate.
26 Jan 2023
‘Collateral damage’ from normal cell function may cause mutations that play a role in cancer
APOBEC1 enzyme likely responsible for two mutational signatures found in many cancers in small intestine
19 Jan 2023
Bowel cancer mutations that impact immunotherapy identified
Researchers used CRISPR and mini tumours to discover more about how cancer develops and responds to the body’s immune response.